Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease
Dennis J. Selkoe
Dennis J. Selkoe
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1375-1381. https://doi.org/10.1172/JCI16783.
View: Text | PDF
Perspective

Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease

  • Text
  • PDF
Abstract

Perspective

Authors

Dennis J. Selkoe

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Hypothetical model of the role of PS in Notch and APP processing. The di...
Hypothetical model of the role of PS in Notch and APP processing. The diagram shows the predicted eight–TM domain topology of PS, which occurs principally as a cleaved heterodimer. Some Notch and APP molecules form complexes with PS. Two aspartate residues (D) in TM6 and TM7 of PS are required for the cleavages of Notch and APP within their TM domains, and these are predicted to align with the respective sites of cleavage in the two substrates. It is likely that PS directly effects these cleavages, as part of a multi-protein complex (i.e.,γ-secretase). PS-mediated proteolysis of both Notch and APP is preceded by ectodomain shedding mediated by certain ADAM proteases. Alternatively, a subset of APP holoproteins can undergo ectodomain shedding by β-secretase. Several motifs are depicted in Notch: EGF-like repeats (yellow circles), LNG repeats (red diamonds), a single TM (orange box), the RAM23 domain (blue square), a nuclear localization sequence (red rectangle), and six cdc10/ankyrin repeats (green ovals). Following the putative intramembranous cleavage mediated by PS, the Notch intracellular domain is released to the nucleus to activate transcription of target genes. APP contains the Aβ region (light blue box), which is released into the lumen after sequential cleavages of APP by β-secretase and then γ-secretase/PS. Some of the AICD reaches the nucleus as well.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts